Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

728 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma.
Fanucci K, Pilat MJ, Shyr D, Shyr Y, Boerner S, Li J, Durecki D, Drappatz J, Puduvalli V, Lieberman FS, Gonzalez J, Giglio P, Ivy SP, Bindra RS, Omuro A, LoRusso P. Fanucci K, et al. Among authors: shyr y, shyr d. Cancer Res Commun. 2023 Feb 2;3(2):192-201. doi: 10.1158/2767-9764.CRC-22-0436. eCollection 2023 Feb. Cancer Res Commun. 2023. PMID: 36968138 Free PMC article. Clinical Trial.
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E. Cardin DB, et al. Among authors: shyr y. Cancer Med. 2014 Jun;3(3):572-9. doi: 10.1002/cam4.208. Epub 2014 Feb 12. Cancer Med. 2014. PMID: 24574334 Free PMC article. Clinical Trial.
Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.
Alvarado-Cruz I, Mahmoud M, Khan M, Zhao S, Oeck S, Meas R, Clairmont K, Quintana V, Zhu Y, Porciuncula A, Wyatt H, Ma S, Shyr Y, Kong Y, LoRusso PM, Laverty D, Nagel ZD, Schalper KA, Krauthammer M, Sweasy JB. Alvarado-Cruz I, et al. Among authors: shyr y. Biochem Pharmacol. 2021 Feb;184:114359. doi: 10.1016/j.bcp.2020.114359. Epub 2020 Dec 4. Biochem Pharmacol. 2021. PMID: 33285109 Free PMC article.
A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop.
Von Hoff DD, Clark GM, Coltman CA, Disis ML, Eckhardt SG, Ellis LM, Foti M, Garrett-Mayer E, Gönen M, Hidalgo M, Hilsenbeck SG, Littlefield JH, LoRusso PM, Lyerly HK, Meropol NJ, Patel JD, Piantadosi S, Post DA, Regan MM, Shyr Y, Tempero MA, Tepper JE, Von Roenn J, Weiner LM, Young DC, Vu NV. Von Hoff DD, et al. Among authors: shyr y. Clin Cancer Res. 2021 Oct 15;27(20):5472-5481. doi: 10.1158/1078-0432.CCR-21-1799. Epub 2021 Jul 26. Clin Cancer Res. 2021. PMID: 34312215 Free PMC article.
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. Kim JW, et al. Among authors: shyr y. J Clin Oncol. 2023 Feb 1;41(4):871-880. doi: 10.1200/JCO.21.02947. Epub 2022 Oct 18. J Clin Oncol. 2023. PMID: 36256912 Free PMC article. Clinical Trial.
728 results